Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

InSightec Granted CFDA Approval for Fibroid Treatment Device

publication date: Jul 29, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
InSightec Ltd, an Israeli medical device maker, reported that its ExAblate System was approved for China marketing by the CFDA. ExAblate is a focused ultrasound device combined with continuous MRI imaging that is used to treat uterine fibroids non-invasively. GE Healthcare is majority owner of InSightec and contributed 90% of its $31 million C funding last year. More details....

Stock Symbol: (NYSE: GE)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners